CRIS$0.6708+1.48%
Curis Inc.
Sector: Biological Products, (No Diagnostic Substances)Industry: BiotechnologyCountry: USExchange: Nasdaq
Mkt Cap:$4.48M
Float & O/S:6.66M / 6.68M
Inst Own:10.1%
DilutionScan read 38 of CURIS INC's SEC filings and found 16 warrant series, 1 convertible, 1 ATM program, 5 shelf registrations, 2 S-1 registrations and 3 completed offerings on file for CRIS. The latest dilution event on file is a warrant issuance on Oct 19, 2026. Analysis updated Oct 24, 2026.
Signal8 Summary
CRIS
Imminent cash shortfall and reverse split
Snapshot
Curis is a clinical-stage biotechnology company burning cash at an unsustainable rate. With $27.2M in annual free cash flow outflows and only $5.1M in the bank, the company has roughly a two-month cash runway.
What's Happening Right Now
- : Curis priced a $5.6M public offering to raise capital, a necessary step given its short cash runway.
- : The company dosed the first five patients in its TakeAim CLL study, with initial data expected in December 2026.
- : Updated data for emavusertib showed a 100% response rate in BTKi-naive PCNSL patients and increased guidance for year-end CLL data.
- : The 1-for-20 reverse stock split approved by shareholders became effective to regain compliance with Nasdaq listing rules.
- : Curis solicited shareholder approval for a reverse split after receiving a Nasdaq delisting notice for trading below $1.00.
